Clinical Trials Browser

Phase 4 × orelabrutinib × 90 days × Clear all

NCT07355699 2026-01-21

Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma

Phase 4 Recruiting

Lymphoma, B-Cell, Marginal Zone